新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 公司 » 第一三共与桑福德-伯纳姆医学研究达成心血管代谢疾病研发合作

第一三共与桑福德-伯纳姆医学研究达成心血管代谢疾病研发合作

来源:生物谷 2014-05-23 09:09

2014年5月22日讯 /生物谷BIOON/ --第一三共制药( Daiichi Sankyo)5月21日宣布,与美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research Institute)签署了一项为期3年的联盟协议,开发用于心血管代谢疾病治疗的首创新药。此次合作,建立于一种开放式创新模式,将弥补靶标发现和临床前药物开发的空白。

此次合作,重点是鉴定、验证和筛选新颖的药物靶标,并研究疾病的新机制。桑福德-伯纳姆医学研究所的团队,将与第一三共心血管-代谢疾病研究实验室,合作鉴定并验证靶标。在验证靶标后,合作团队将开展药物筛选,将利用双方的设施,鉴定能够调节这些靶标的化合物。

去年8月,辉瑞也与桑福德-伯纳姆医学研究所签署了一项为期3年的合作协议,将利用桑福德-伯纳姆医学研究所在疾病生物学和肌肉代谢领域的专业知识,和辉瑞在药物发现领域的专业知识,寻找新的方法来抗击肥胖相关糖尿病。(生物谷Bioon.com)

英文原文:Daiichi Sankyo, Sanford-Burnham Partner on Novel Drug Targets

Wed, 05/21/2014 - 11:02am

Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co. Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.
 
This collaboration focuses on identifying, validating, and screening novel drug targets, and studying new mechanisms of disease. The Sanford-Burnham team will identify and validate targets in collaboration with Cardiovascular-Metabolics Research Laboratories at Daiichi Sankyo. After the validation of the targets, collaboration teams will conduct drug screening to identify compounds that modulate the targets using facilities at both sites.
 
"The partnership will focus on the broad area of cardiovascular-metabolic diseases, which is a primary research area for Sanford-Burnham as well as a critical unmet medical need worldwide," said Dwight Towler, professor and director of the Cardiovascular Pathobiology Program at Sanford-Burnham. "Strategic partnerships such as this one serve as a key component of our Institute's 10-year vision to translate basic research discoveries into innovative therapies more quickly. Today's announcement represents another milestone for Sanford-Burnham as we connect our expertise in both basic research and drug discovery technology with pharmaceutical partners to implement this patient-oriented initiative."
 
"This is a unique and innovative early-stage drug discovery collaboration," said Dr. Masahiko Ohtsuki, corporate officer and global head of research, Daiichi Sankyo. "The cardiovascular-metabolic area is a key priority for Daiichi Sankyo and we have found a strong, strategic partner in Sanford-Burnham. I am excited about this collaboration and look forward to seeing results of this partnership."

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库